Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by L Hofmann-Xu
Relationship Between the Price Differences in Orphan Drugs With More Than One Benefit Assessment in Amnog and the Potential Influencing Factors
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Is the Proof of an Additional Benefit Under Amnog in Germany More Difficult for Certain Drugs Than for Other Ones?
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Conditional Resolutions in the Amnog Early Benefit Assessment
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Psy165 - Price Differences for Orphan Drugs Across the Eu-5 Countries: A Comparative Assessment
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Non-Quantifiable Benefit Within the German Amnog System: Factors Contributing to Time Limits Set for Benefit Resolutions and Potential Implications on Price Discounts
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Php237 - Overview of German Amnog Dossiers With Price Analysis Before and After Early Benefit Assessment
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
2.5 Years of Amnog in Germany – An Analysis of Benefit Assessment and Net Price Negotiation Trends
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Php293 - Orphan Drugs in Germany - Lessons Learned From Amnog, Best and Worst Practices and Strategic Implications
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Finding More Than One Worm in the Apple
Queue
Computer Science
Pricing and Reimbursement of Orphan Drugs: The Need for More Transparency
Orphanet Journal of Rare Diseases
Medicine
Genetics
Pharmacology
